×
RVL Pharmaceuticals Net Profit Margin 2017-2023 | RVLP
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Profit Margins
Gross Margin
Operating Margin
EBITDA Margin
Pre-Tax Margin
Net Margin
RVL Pharmaceuticals net profit margin from 2017 to 2023. Net profit margin can be defined as net Income as a portion of total sales revenue.
View More
RVL Pharmaceuticals Net Profit Margin 2017-2023 | RVLP
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Profit Margins
Gross Margin
Operating Margin
EBITDA Margin
Pre-Tax Margin
Net Margin
RVL Pharmaceuticals net profit margin from 2017 to 2023. Net profit margin can be defined as net Income as a portion of total sales revenue.
Related Stocks
Company Name
Market
Cap
Zoetis (ZTS)
$79.8B
Takeda Pharmaceutical (TAK)
$43.8B
Merck (MKKGY)
$21B
Astellas Pharma (ALPMY)
$20.2B
Sandoz Group AG (SDZNY)
$19.8B
United Therapeutics (UTHR)
$18.3B
Summit Therapeutics (SMMT)
$15.8B
Neurocrine Biosciences (NBIX)
$12.7B
Shionogi (SGIOY)
$12.5B
Catalent (CTLT)
$10.8B
Madrigal Pharmaceuticals (MDGL)
$7.6B
Jazz Pharmaceuticals (JAZZ)
$7.6B
Orion OYJ (ORINY)
$6.8B
Corcept Therapeutics (CORT)
$6.2B
Ionis Pharmaceuticals (IONS)
$6.2B
Crinetics Pharmaceuticals (CRNX)
$4.9B
PTC Therapeutics (PTCT)
$3.4B
Dyne Therapeutics (DYN)
$2.9B
Catalyst Pharmaceuticals (CPRX)
$2.9B
Arrowhead Pharmaceuticals (ARWR)
$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.7B
Soleno Therapeutics (SLNO)
$2.5B
NewAmsterdam Pharma (NAMS)
$2.2B
Recursion Pharmaceuticals (RXRX)
$2B
Centessa Pharmaceuticals (CNTA)
$1.9B
Harrow (HROW)
$1.9B
Ocular Therapeutix (OCUL)
$1.7B
Xencor (XNCR)
$1.7B
ARS Pharmaceuticals (SPRY)
$1.7B
BioCryst Pharmaceuticals (BCRX)
$1.6B